{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for acetohydroxamic root_modifications_agentModifications_agentSubstance_refPname in root_modifications_agentModifications_agentSubstance_refPname (approximate match)
Status:
US Approved Rx
(2021)
Source:
BLA761194
(2021)
Source URL:
First approved in 2021
Source:
BLA761194
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00027248: Phase 3 Interventional Completed Sepsis
(2000)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:iodine (¹²⁴I) evuzamitide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00951405: Phase 2 Interventional Completed Congenital Bleeding Disorder
(2009)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:157002
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1994)
Source:
NDA020287
(1994)
Source URL:
First approved in 1994
Source:
NDA020287
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01621243: Phase 1/Phase 2 Interventional Terminated Metastatic Pancreatic Cancer
(2012)
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT02515838: Phase 2 Interventional Completed Sickle-Cell Disease
(2015)
Source URL:
Class:
POLYMER
